217 related articles for article (PubMed ID: 23113544)
1. Regulation of human RNase-L by the miR-29 family reveals a novel oncogenic role in chronic myelogenous leukemia.
Lee TY; Ezelle HJ; Venkataraman T; Lapidus RG; Scheibner KA; Hassel BA
J Interferon Cytokine Res; 2013 Jan; 33(1):34-42. PubMed ID: 23113544
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.
Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L
Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856
[TBL] [Abstract][Full Text] [Related]
3. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.
Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
Cancer Lett; 2015 Jan; 356(2 Pt B):597-605. PubMed ID: 25305453
[TBL] [Abstract][Full Text] [Related]
4. miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2.
Pan B; Yang J; Wang X; Xu K; Ikezoe T
Exp Hematol; 2018 Dec; 68():80-88.e2. PubMed ID: 30195077
[TBL] [Abstract][Full Text] [Related]
5. miR-181a post-transcriptionally downregulates oncogenic RalA and contributes to growth inhibition and apoptosis in chronic myelogenous leukemia (CML).
Fei J; Li Y; Zhu X; Luo X
PLoS One; 2012; 7(3):e32834. PubMed ID: 22442671
[TBL] [Abstract][Full Text] [Related]
6. 2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells.
Maran A; Waller CF; Paranjape JM; Li G; Xiao W; Zhang K; Kalaycio ME; Maitra RK; Lichtin AE; Brugger W; Torrence PF; Silverman RH
Blood; 1998 Dec; 92(11):4336-43. PubMed ID: 9834240
[TBL] [Abstract][Full Text] [Related]
7. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
Xu C; Fu H; Gao L; Wang L; Wang W; Li J; Li Y; Dou L; Gao X; Luo X; Jing Y; Chim CS; Zheng X; Yu L
Oncogene; 2014 Jan; 33(1):44-54. PubMed ID: 23208504
[TBL] [Abstract][Full Text] [Related]
8. Functional screen analysis reveals miR-3142 as central regulator in chemoresistance and proliferation through activation of the PTEN-AKT pathway in CML.
Zhao L; Shan Y; Liu B; Li Y; Jia L
Cell Death Dis; 2017 May; 8(5):e2830. PubMed ID: 28542127
[TBL] [Abstract][Full Text] [Related]
9. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481
[TBL] [Abstract][Full Text] [Related]
10. A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia.
Bi L; Zhou B; Li H; He L; Wang C; Wang Z; Zhu L; Chen M; Gao S
BMC Cancer; 2018 Feb; 18(1):182. PubMed ID: 29439669
[TBL] [Abstract][Full Text] [Related]
11. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
12. miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein.
Li Y; Wang H; Tao K; Xiao Q; Huang Z; Zhong L; Cao W; Wen J; Feng W
Exp Cell Res; 2013 May; 319(8):1094-101. PubMed ID: 23428668
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia.
Xishan Z; Ziying L; Jing D; Gang L
Sci Rep; 2015 Jul; 5():12460. PubMed ID: 26228085
[TBL] [Abstract][Full Text] [Related]
14. Human RNase L tunes gene expression by selectively destabilizing the microRNA-regulated transcriptome.
Rath S; Donovan J; Whitney G; Chitrakar A; Wang W; Korennykh A
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):15916-21. PubMed ID: 26668391
[TBL] [Abstract][Full Text] [Related]
15. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells.
Venturini L; Battmer K; Castoldi M; Schultheis B; Hochhaus A; Muckenthaler MU; Ganser A; Eder M; Scherr M
Blood; 2007 May; 109(10):4399-405. PubMed ID: 17284533
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-582-3p negatively regulates cell proliferation and cell cycle progression in acute myeloid leukemia by targeting cyclin B2.
Li H; Tian X; Wang P; Huang M; Xu R; Nie T
Cell Mol Biol Lett; 2019; 24():66. PubMed ID: 31844417
[TBL] [Abstract][Full Text] [Related]
17. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
[TBL] [Abstract][Full Text] [Related]
18. The proto-oncogene Pim-1 is a target of miR-33a.
Thomas M; Lange-Grünweller K; Weirauch U; Gutsch D; Aigner A; Grünweller A; Hartmann RK
Oncogene; 2012 Feb; 31(7):918-28. PubMed ID: 21743487
[TBL] [Abstract][Full Text] [Related]
19. MiR-124-3p/B4GALT1 axis plays an important role in SOCS3-regulated growth and chemo-sensitivity of CML.
Liu YX; Wang L; Liu WJ; Zhang HT; Xue JH; Zhang ZW; Gao CJ
J Hematol Oncol; 2016 Aug; 9(1):69. PubMed ID: 27516205
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-520a-5p displays a therapeutic effect upon chronic myelogenous leukemia cells by targeting STAT3 and enhances the anticarcinogenic role of capsaicin.
Kaymaz BT; Cetintaş VB; Aktan C; Kosova B
Tumour Biol; 2014 Sep; 35(9):8733-42. PubMed ID: 24870597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
